This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Fully understand the study and voluntarily sign the informed consent form.
18-75 years of age;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
Life expectancy ≥ 12 weeks.
Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Parallel
ZG005 for Injection
Biological/Vaccine10 mg/kg or 20 mg/kg administered intravenously Q3w
Bevacizumab
Biological/Vaccine15 mg/kg administered intravenously Q3w
Sintilimab
Biological/Vaccine200 mg administered intravenously Q3w
Bevacizumab
Biological/Vaccine15 mg/kg administered intravenously Q3w
progression free survival，PFS
defined as the time from receiving treatment until disease progression or death from any cause, whichever happens first.
Click on the lead sponsor to view all of their trials.
